ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. will acquire neuroscience-focused Caraway Therapeutics for up to $610 million in up-front and milestone payments. Merck has been a shareholder in the biotechnology firm since it launched in 2018 and will now purchase all outstanding shares in the company. In Caraway, Merck gets a pipeline of small-molecule candidates for treating neurodegenerative diseases. These drugs activate cellular recycling processes by modifying lysosomal function.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter